Form 4: Vanda Pharmaceuticals SVP & General Counsel Timothy Williams Reports Acquisition of 125,000 Shares

Timothy Williams, SVP & General Counsel of Vanda Pharmaceuticals, reports acquiring 125,000 shares of common stock through a restricted stock unit award.

Summary

• On February 18, 2025, Timothy Williams, the SVP & General Counsel of Vanda Pharmaceuticals, reported acquiring 125,000 shares of Vanda Pharmaceuticals common stock.
• These shares were acquired through a time-based restricted stock unit (RSU) award.
• The RSU vests in four equal annual installments, starting on March 1, 2026, contingent upon continuous employment with Vanda Pharmaceuticals.
• Vested shares will be delivered on the first permissible trading day after each vesting date.
• Following the transaction, Williams directly owns 321,825 shares of Vanda Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider stock activity, which doesn't inherently suggest positive or negative company performance.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The RSU vests in four equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Comparison to Industry Standards

• RSUs are a common form of equity compensation used by publicly traded companies to align the interests of employees and shareholders.
• The vesting schedule of four equal annual installments is a typical arrangement for RSU awards.

Key Dates

Keywords

Vanda Pharmaceuticals, Timothy Williams, Form 4, Beneficial Ownership, Restricted Stock Unit, VNDA, Insider Trading